Johnson Chemical Pharmaceutical Works Co., Ltd. (TPEX: 4747)
Taiwan
· Delayed Price · Currency is TWD 70.10
+0.10 (0.14%)
Nov 21, 2024, 1:16 PM CST
Johnson Chemical Pharmaceutical Works Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 618.33 | 606.71 | 494.67 | 411.49 | 424.02 | 425.34 | Upgrade
|
| Revenue Growth (YoY) | 4.25% | 22.65% | 20.21% | -2.95% | -0.31% | 3.26% | Upgrade
|
| Cost of Revenue | 371.38 | 362.08 | 290.29 | 239.57 | 231.83 | 233.89 | Upgrade
|
| Gross Profit | 246.95 | 244.63 | 204.38 | 171.92 | 192.18 | 191.45 | Upgrade
|
| Selling, General & Admin | 133.33 | 128.45 | 108.45 | 100.72 | 103.57 | 102.72 | Upgrade
|
| Research & Development | 17.49 | 17.27 | 13.25 | 8.92 | 13.08 | 9.84 | Upgrade
|
| Operating Expenses | 150.26 | 145.8 | 122.58 | 109.64 | 116.17 | 112.61 | Upgrade
|
| Operating Income | 96.69 | 98.83 | 81.79 | 62.29 | 76.01 | 78.83 | Upgrade
|
| Interest Expense | -3.73 | -4.6 | -1.06 | -1.08 | -0.79 | -0.02 | Upgrade
|
| Interest & Investment Income | 13.93 | 6.33 | 0.49 | 0.57 | 0.99 | 1.44 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.06 | 0.04 | 0.1 | -0.66 | -0.02 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.4 | 0.28 | 0.21 | 0.83 | 0.33 | 1.18 | Upgrade
|
| EBT Excluding Unusual Items | 107.34 | 100.88 | 81.53 | 61.95 | 76.51 | 81.44 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.37 | - | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.01 | - | -0.01 | 0.05 | - | Upgrade
|
| Pretax Income | 105.97 | 100.89 | 81.53 | 61.94 | 76.55 | 81.44 | Upgrade
|
| Income Tax Expense | 24.15 | 21.19 | 16.68 | 12.84 | 12.99 | 16.97 | Upgrade
|
| Net Income | 81.83 | 79.7 | 64.85 | 49.1 | 63.56 | 64.47 | Upgrade
|
| Net Income to Common | 81.83 | 79.7 | 64.85 | 49.1 | 63.56 | 64.47 | Upgrade
|
| Net Income Growth | 1.49% | 22.90% | 32.08% | -22.75% | -1.41% | 12.54% | Upgrade
|
| Shares Outstanding (Basic) | 45 | 36 | 30 | 30 | 30 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 47 | 38 | 30 | 30 | 30 | 30 | Upgrade
|
| Shares Change (YoY) | 37.71% | 26.25% | -0.07% | -0.04% | 0.01% | 0.03% | Upgrade
|
| EPS (Basic) | 1.83 | 2.24 | 2.16 | 1.64 | 2.12 | 2.15 | Upgrade
|
| EPS (Diluted) | 1.83 | 2.18 | 2.16 | 1.63 | 2.11 | 2.14 | Upgrade
|
| EPS Growth | -24.88% | 0.88% | 32.52% | -22.75% | -1.40% | 12.63% | Upgrade
|
| Free Cash Flow | 58.06 | 103.84 | 29.98 | 15.06 | -90.41 | 56.44 | Upgrade
|
| Free Cash Flow Per Share | 1.25 | 2.73 | 1.00 | 0.50 | -3.00 | 1.87 | Upgrade
|
| Dividend Per Share | 1.500 | 1.500 | 2.000 | 1.450 | 1.920 | 1.800 | Upgrade
|
| Dividend Growth | -25.00% | -25.00% | 37.93% | -24.48% | 6.67% | 9.09% | Upgrade
|
| Gross Margin | 39.94% | 40.32% | 41.32% | 41.78% | 45.32% | 45.01% | Upgrade
|
| Operating Margin | 15.64% | 16.29% | 16.54% | 15.14% | 17.93% | 18.53% | Upgrade
|
| Profit Margin | 13.23% | 13.14% | 13.11% | 11.93% | 14.99% | 15.16% | Upgrade
|
| Free Cash Flow Margin | 9.39% | 17.11% | 6.06% | 3.66% | -21.32% | 13.27% | Upgrade
|
| EBITDA | 118.08 | 119.94 | 100.06 | 77.57 | 89.24 | 91 | Upgrade
|
| EBITDA Margin | 19.10% | 19.77% | 20.23% | 18.85% | 21.05% | 21.39% | Upgrade
|
| D&A For EBITDA | 21.39 | 21.11 | 18.27 | 15.29 | 13.23 | 12.17 | Upgrade
|
| EBIT | 96.69 | 98.83 | 81.79 | 62.29 | 76.01 | 78.83 | Upgrade
|
| EBIT Margin | 15.64% | 16.29% | 16.54% | 15.14% | 17.93% | 18.53% | Upgrade
|
| Effective Tax Rate | 22.78% | 21.00% | 20.46% | 20.73% | 16.97% | 20.84% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.